Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/03/26	2.020 $	-1.46%	3,636,148
16/03/26	2.050 $	-2.84%	3,367,634
13/03/26	2.110 $	-1.40%	2,190,648
12/03/26	2.140 $	-2.28%	2,972,513
11/03/26	2.190 $	+0.46%	4,427,766

Delayed Quote Australian S.E.

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Mesoblast Leads Global Regenerative Therapy Expansion

February 13, 2026 at 09:51 am

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.050AUD

Average target price

3.898AUD

Spread / Average Target

+90.12%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Australian S.E. Other stock markets 05:10:21 17/03/2026 GMT			5-day change	1st Jan Change
2.020 ^AUD	-1.46%		-7.34%	-25.74%

03-12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
03-11	Mesoblast Appoints Head of Clinical Development, Medical Affairs	MT

Capitalization	2.65B 1.86B 1.62B 1.47B 1.4B 2.55B 172B 17.47B 6.94B 82.36B 7B 6.85B 297B	P/E ratio 2026 *	-34.3x	P/E ratio 2027 *	42x
Enterprise value	2.62B 1.85B 1.61B 1.46B 1.39B 2.53B 171B 17.32B 6.88B 81.62B 6.93B 6.79B 294B	EV / Sales 2026 *	14.6x	EV / Sales 2027 *	7.59x
Free-Float	74.47%	Yield 2026 *	-	Yield 2027 *	-

03-12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
03-11	Mesoblast Appoints Head of Clinical Development, Medical Affairs	MT
03-09	Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys	MT
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-27	Mesoblast Limited Provides Revenue Guidance for Fiscal Year 2026	CI
02-27	Mesoblast posts HY total revenues $51.3 million	RE
02-27	Mesoblast sees full-year fiscal 2026 Ryoncil net revenue to range between $110 million and $120 million	RE
02-27	ASX Biggest Losers	MT
02-27	Mesoblast Limited, H1 2026 Earnings Call, Feb 27, 2026
02-26	Mesoblast Posts Narrower Fiscal H1 Loss, Higher Revenue	MT
02-26	Mesoblast Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-13	Mesoblast Leads Global Regenerative Therapy Expansion
02-12	Mesoblast Limited Provides Data Presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for Blood and Marrow Transplant Research in Salt Lake City, Utah	CI

03-09	Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys	MT
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
01-14	Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies	MT
11-05	Mesoblast to Meet US FDA on Opioid Cessation Data for Back Pain Drug	MT
11-05	Mesoblast Says US FDA Schedules Meeting in Early December to Discuss Data from Chronic Low Back Pain Study	MT

Mesoblast Limited Share Price

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Valuation: Mesoblast Limited

Chart: Mesoblast Limited

Latest news: Mesoblast Limited

Last Transcript: Mesoblast Limited

Analysts' recommendations: Mesoblast Limited

Press Releases: Mesoblast Limited

News in other languages: Mesoblast Limited

Quotes and Performance

Course Extremes

Managers and Directors: Mesoblast Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-11	Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast	AQ
03-03	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them	AQ
02-27	Ryoncil® Profits Underpinning Substantial Growth Pipeline	AQ
02-23	MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST	AQ
02-20	Mesoblast Financial Results and Corporate Update Webcast	AQ

18/02/25	De nieuwste transacties van de sterbeheerders
15/11/21	MÄRKTE ASIEN/Etwas fester - Chinas Börsen hinken hinterher
18/12/20	EN DIRECT DES MARCHES : Renault, Vivendi, EssilorLuxottica, Kering, Vinci, Microsoft, Coca-Cola, Enel, Fedex...
15/12/20	MÄRKTE ASIEN/Corona-Sorgen lassen Anleger vorsichtig agieren
20/11/20	Aktien Schweiz: Wenig verändert - Anleger unschlüssig

1 day	-1.46%
1 week	-7.34%
Current month	-9.82%
1 month	-16.18%
3 months	-27.86%
6 months	-12.17%
Current year	-25.74%

1 week	2.02	2.23
1 month	1.95	2.63
Current year	1.95	3.31
1 year	1.52	3.31
3 years	0.26	3.37
5 years	0.26	3.37
10 years	0.26	5.7

Manager	Title	Age	Since
Silviu Itescu CEO	Chief Executive Officer	69	22/03/2011
James O'Brien DFI	Director of Finance/CFO	59	16/11/2025
Eric Rose CTO	Chief Tech/Sci/R&D Officer	75	31/01/2022

Director	Title	Age	Since
Silviu Itescu BRD	Director/Board Member	69	31/12/2006
Eric Rose BRD	Director/Board Member	75	14/04/2013
William Burns BRD	Director/Board Member	78	05/03/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MESOBLAST LIMITED	-1.46%	-7.34%	-2.88%	+113.76%	1.86B
LONZA GROUP AG	-0.51%	-3.30%	-14.27%	-10.03%	42.95B
BEONE MEDICINES AG	+1.97%	-4.18%	+11.75%	+28.87%	32.12B
CELLTRION, INC.	-2.68%	-1.96%	+11.77%	+44.06%	29.32B
IQVIA HOLDINGS INC.	+0.10%	-7.65%	-10.96%	-16.06%	27.68B
REVOLUTION MEDICINES, INC.	+4.36%	-0.79%	+153.07%	+345.14%	19.62B
ASCENDIS PHARMA A/S	+2.23%	-3.71%	+51.02%	+110.62%	14.18B
MEDPACE HOLDINGS, INC.	+0.72%	-5.20%	+39.60%	+148.90%	12.87B
EUROFINS SCIENTIFIC SE	+0.49%	-3.27%	+22.77%	+0.39%	12.39B
IONIS PHARMACEUTICALS, INC.	+1.62%	-4.01%	+119.48%	+106.69%	11.95B
Average	+0.68%	-3.81%	+38.13%	+87.23%	20.49B
Weighted average by Cap.	+0.56%	-3.93%	+28.04%	+63.88%

	2026 *	2027 *
Net sales	180M 127M 110M 99.78M 95.2M 173M 11.68B 1.19B 471M 5.59B 475M 465M 20.16B	330M 233M 203M 184M 175M 318M 21.48B 2.18B 867M 10.28B 873M 855M 37.07B
Net income	-56.87M -40.08M -34.91M -31.61M -30.16M -54.85M -3.7B -376M -149M -1.77B -150M -147M -6.39B	53.72M 37.86M 32.98M 29.86M 28.49M 51.82M 3.5B 355M 141M 1.67B 142M 139M 6.03B
Net Debt	-23.86M -16.82M -14.65M -13.26M -12.65M -23.02M -1.55B -158M -62.62M -743M -63.11M -61.78M -2.68B	-138M -97.45M -84.87M -76.85M -73.32M -133M -9B -913M -363M -4.3B -366M -358M -15.52B